首页> 美国卫生研究院文献>Hematology Transfusion and Cell Therapy >Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide thalidomide and dexamethasone: is granulocyte-colony stimulating factor alone enough?

【2h】

Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide thalidomide and dexamethasone: is granulocyte-colony stimulating factor alone enough?

机译：造血干细胞动员用于先前接触过环磷酰胺沙利度胺和地塞米松的多发性骨髓瘤患者的自体移植：单独使用粒细胞集落刺激因子是否足够？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Hematology Transfusion and Cell Therapy
作者
Afonso Celso Vigorito;
展开▼
作者单位

展开▼
年(卷),期 2016(38),4
年度 2016
页码 281–282
总页数 2
原文格式 PDF
正文语种
中图分类血液学检验;
关键词

相似文献

外文文献
中文文献
专利

1. Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough? [J] . Afonso Celso Vigorito Hematology, Transfusion and Cell Therapy . 2016,第4期

机译：造血干细胞动员用于先前接触过环磷酰胺，沙利度胺和地塞米松的多发性骨髓瘤患者的自体移植：仅粒细胞集落刺激因子就足够了吗？
2. Canadian Retrospective Multicentric Study Comparing the Combination of Bortezomib, Cyclophosphamide and Dexamethasone (Cybord) Versus Bortezomib, Thalidomide and Dexamethasone (VTD) Versus Bortezomib and Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Hematopoietic Stem Cell Transplantation (HCT) [J] . Yamga Eric, Leblanc Richard, Boudreault Jean-Samuel Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：加拿大回顾性的多中心研究比较硼佐米，环磷酰胺和地塞米松（Cybord）的组合与硼替佐米，沙利度胺和地塞米松（VTD）与硼喹啉和地塞米松（VD）进行新诊断的多发性脑膜患者，其中有资格获得自体造血干细胞移植（HCT）
3. Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen? [J] . Edvan de Queiroz Crusoe, Fabiana Higashi, Gracia Aparecida Martinez, Hematology, Transfusion and Cell Therapy . 2016,第4期

机译：在环磷酰胺，沙利度胺和地塞米松方案诱导的多发性骨髓瘤患者中，单独使用粒细胞集落刺激因子来动员祖细胞是否可行？
4. HIGH DOSE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PATIENTS WITH PRIMARY SYSTEMIC AMYLOIDOSIS (AL): AN ABMTR STUDY [C] . DH Vesole, W Perez, D Reece, International Symposium on Amyloidosis . 2005

机译：具有自体造血干细胞移植（HSCT）的高剂量治疗用于初级全身淀粉样蛋白症（AL）的患者：ABMTR研究
5. Monocytic Cells Mediate Granulocyte-Colony Stimulating Factor-Induced Mobilization of Hematopoietic Stem and Progenitor Cells [D] . Rao, Mahil 2013

机译：单核细胞介导粒细胞集落刺激因子诱导的造血干细胞和祖细胞动员。
6. Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide thalidomide and dexamethasone regimen? [O] . Edvan de Queiroz Crusoe, Fabiana Higashi, Gracia Aparecida Martinez, 2016

机译：在环磷酰胺沙利度胺和地塞米松方案诱导的多发性骨髓瘤患者中单独使用粒细胞集落刺激因子来动员祖细胞是否可行？
7. Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough? [O] . Afonso Celso Vigorito 2016

机译：造血干细胞动员用于先前接触环磷酰胺，沙利度胺和地塞米松的多发性骨髓瘤患者的自体移植：足够单独使用粒细胞集落刺激因子吗？

Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide thalidomide and dexamethasone: is granulocyte-colony stimulating factor alone enough?

著录项

相似文献

相关主题

期刊订阅